• Home
  • About CML
    • Who We Are
    • What we Do
    • Mission & Vision
    • The Patient Advisory Board
  • What is CML
  • Treatments
    • Access
    • Living Well
    • Clinical Trials
  • News
  • Contact
  • Home
  • About CML
    • Who We Are
    • What we Do
    • Mission & Vision
    • The Patient Advisory Board
  • What is CML
  • Treatments
    • Access
    • Living Well
    • Clinical Trials
  • News
  • Contact

Bosulif Conditionally Approved in Canada – Approuve Conditionnellement

•22 October 2024

Health Canada CONDITIONALLY approves BOSULIF – a new medication for chronic myelogenous leukemia
Approval provides new treatment option for Canadians suffering from rare cancer

SANTÉ CANADA APPROUVE CONDITIONNELLEMENT L’EMPLOI DE BOSULIF – UN NOUVEAU MÉDICAMENT CONTRE LA LEUCÉMIE MYÉLOÏDE CHRONIQUE
Les Canadiens bénéficient ainsi d’une nouvelle option de traitement pour un cancer rare 

Previous PostCanadian CML Patients being treated with iClusig (Ponatinib)Next PostBosulif (™) (bosutinib)

Related Posts

ACCESS TO AFFORDABLE MEDICINE FOR ALL

CML Access to Medicine

APO-IMATINIB

Apo – imatinib – Treatment for CML



Society of Canada provides support, education and information on CML, current and emerging treatments and research initiatives for people living with CML and their families.

Contact Centre

1 (514) 239-5488

All Across Canada

Mon – Fri: 8.00am 6.00pm

Member Resources

  • About CML
  • What is CML
  • Contact Us
  • Treatments
  • News
  • Videos

Our Newsletter

Copyright ©2024 CML. All Rights Reserved. Legal and Privacy.